Biomarkers in Systemic Histiocytosis
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ·
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Bio-Histio is an observational study in adults with systemic histiocytosis, a rare group of inflammatory diseases that can affect multiple organs. Researchers aim to identify new biological clues, or biomarkers, that help explain how these conditions start and progress, how they relate to symptoms and organ involvement, and how people respond to treatments. The study plans to follow about 500 participants over up to 10 years, collecting health information during routine care and using advanced laboratory tests to look for these biomarkers.
If you are eligible, you must be 18 or older and have a confirmed diagnosis of systemic histiocytosis being followed at the Pitié-Salpêtrière Hospital in Paris. Exclusion criteria include pregnancy, not having French health coverage, or certain legal protections. Participation involves samples collected mainly from routine blood work: up to six extra tubes of blood (about 42 mL) may be taken for research, and optional saliva, urine, or stool samples may also be collected. This is an observational study (not a drug trial), so your standard medical care will continue as usual. The researchers will store de-identified data and may share it with other researchers to study biomarkers and how they relate to disease activity, prognosis, and treatment response.
Gender
ALL
Eligibility criteria
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported